{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:27:17Z","timestamp":1790270837521,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Tobira Therapeutics, Inc."}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.cct.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T04:16:44Z","timestamp":1456892204000},"page":"356-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"special_numbering":"C","title":["Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00063622","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01092104","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01265498","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01338883","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02217475","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Scott","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred","family":"Gottwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2016.02.012_bb0005","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2012.128","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"107","author":"Chalasani","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cct.2016.02.012_bb0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2004.04.004","article-title":"The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease","volume":"8","author":"McCullough","year":"2004","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.cct.2016.02.012_bb0015","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0261-5614(99)80015-6","article-title":"Non-alcoholic fatty liver: another feature of the metabolic syndrome?","volume":"18","author":"Cortez-Pinto","year":"1999","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.cct.2016.02.012_bb0025","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2016.02.012_bb0030","author":"World Gastroenterology Organisation (WGO)"},{"key":"10.1016\/j.cct.2016.02.012_bb0035","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2016.02.012_bb0040","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/jlts.2001.25453","article-title":"Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease","volume":"7","author":"Charlton","year":"2001","journal-title":"Liver Transpl."},{"key":"10.1016\/j.cct.2016.02.012_bb0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2016.02.012_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2016.02.012_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cct.2016.02.012_bb0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cct.2016.02.012_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fphys.2012.00213","article-title":"The role of chemokines in acute liver injury","volume":"3","author":"Saiman","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cct.2016.02.012_bb0070","doi-asserted-by":"crossref","first-page":"G949","DOI":"10.1152\/ajpgi.00215.2003","article-title":"Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration","volume":"285","author":"Schwabe","year":"2003","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cct.2016.02.012_bb0075","first-page":"1858","article-title":"CCR1 and CCR5 promote hepatic fibrosis in mice","volume":"119","author":"Seki","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2016.02.012_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.22952","article-title":"CCR2 promotes hepatic fibrosis in mice","volume":"50","author":"Seki","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0085","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2353\/ajpath.2009.080632","article-title":"Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice","volume":"174","author":"Mitchell","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cct.2016.02.012_bb0090","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2016.02.012_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.22950","article-title":"Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis","volume":"50","author":"Karlmark","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0100","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cct.2016.02.012_bb0105","doi-asserted-by":"crossref","first-page":"G200","DOI":"10.1152\/ajpgi.2001.281.1.G200","article-title":"Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine","volume":"281","author":"Rivera","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cct.2016.02.012_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2016.02.012_bb0115","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1053\/j.gastro.2007.02.033","article-title":"Gene expression profiles during hepatic stellate cell activation in culture and in vivo","volume":"132","author":"De Minicis","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2016.02.012_bb0120","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/hep.26429","article-title":"Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice","volume":"58","author":"Pradere","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013577","article-title":"Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients","volume":"5","author":"Bertola","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2016.02.012_bb0130","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1128\/AAC.00713-10","article-title":"Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-na\u00efve patients","volume":"55","author":"Marier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2016.02.012_bb0135","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/QAD.0000000000000988","article-title":"A 48-week randomized Phase 2b study evaluating cenicriviroc vs. efavirenz in treatment-naive HIV-infected adults with CCR5-tropic virus","volume":"30","author":"Thompson","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cct.2016.02.012_bb0140","first-page":"221A","article-title":"Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH","volume":"58","author":"Lefebvre","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0145","first-page":"1381A","article-title":"Significant anti-fibrotic activity of cenicriviroc, a dual CCR2\/CCR5 antagonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis","volume":"58","author":"Hong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0150","first-page":"424A","article-title":"Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48weeks","volume":"60","author":"Thompson","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0155","series-title":"Frontiers in Drug Development for Viral Hepatitis, 2015, Hawaii, USA. Abstract","article-title":"CCR2\/CCR5 antagonism with cenicriviroc decreases fibrosis scores in HIV-infected patients. Presented at HEP DART","author":"Sherman","year":"2015"},{"key":"10.1016\/j.cct.2016.02.012_bb0160","series-title":"Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1-infected adults receiving cenicriviroc (CVC) over 48weeks","author":"Thompson","year":"2014"},{"key":"10.1016\/j.cct.2016.02.012_bb0165","first-page":"23","article-title":"Pharmacokinetics and safety of multiple-dose cenicriviroc, a novel, oral, once-daily CCR2 and CCR5 antagonist, in adults with mild or moderate hepatic impairment","volume":"60","author":"Lefebvre","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2016.02.012_bb0175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0180","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.02.012_bb0190","first-page":"1252A","article-title":"The hepatic and extra-hepatic profile of resolution of steatohepatitis induced by GFT-505","volume":"62","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0195","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.02.012_bb0200","article-title":"Pharmacokinetic interactions between cenicriviroc and dolutegravir","author":"Lefebvre","year":"2013"},{"key":"10.1016\/j.cct.2016.02.012_bb0205","first-page":"1301A","article-title":"Cenicriviroc and pioglitazone co-administration shows favorable pharmacokinetics and safety in healthy subjects","volume":"62","author":"Gottwald","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2016.02.012_bb0210","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/mp400286s","article-title":"Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound","volume":"10","author":"Menning","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.cct.2016.02.012_bb0215","author":"National Cancer Institute"},{"key":"10.1016\/j.cct.2016.02.012_bb0220","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2016.02.012_bb0225","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171441630026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171441630026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T01:10:02Z","timestamp":1567645802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171441630026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":45,"alternative-id":["S155171441630026X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2016.02.012","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}